SCHEMBL6894785

SCHEMBL6894785

CC(=O)c1cc2cc(Cl)ccc2o1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.67
HSD17B10 Q99714 3/20 0.67
ALDH1A1 P00352 3/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
GAA P10253 2/20 0.67
LMNA P02545 1/20 0.67
GLA P06280 1/20 0.67
HPGD P15428 1/20 0.67
CASP1 P29466 1/20 0.67
BRCA1 P38398 1/20 0.67
CASP7 P55210 1/20 0.67
MAOB P27338 3/20 0.64
HRH4 Q9H3N8 1/20 0.58
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
GPR35 Q9HC97 1/20 0.53
ALOX5 P09917 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16795656 0.86 CA9 (0.64) KDM4EHSD17B10ALDH1A1SMN1; SMN2GAA
SCHEMBL3613922 0.84 MAOB (0.63) KDM4EHSD17B10ALDH1A1SMN1; SMN2MAOB
SCHEMBL29526778 0.84 PIM1 (0.64) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL705754 0.84 PIM1 (0.64) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL2706216 0.84 KDM4E (0.66) KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL29994222 0.84 KDM4E (0.66) KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL24173779 0.83 TSHR (0.57) KDM4EHSD17B10ALDH1A1SMN1; SMN2GAA
SCHEMBL24681539 0.81 TAS1R3 (0.57) KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL6239408 0.81 HDAC3 (0.60) KDM4EALDH1A1GAAMAOBHRH4
SCHEMBL16595303 0.81 NPC1 (0.56) KDM4EHSD17B10ALDH1A1SMN1; SMN2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200270232-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2020-08-27 US disclosed
US-9802927-B2 Oxadiazine compounds and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-10-31 US disclosed
US-9802927-B2 Oxadiazine compounds and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-10-31 US disclosed
US-9802927-B2 Oxadiazine compounds and methods of use thereof DENALI THERAPEUTICS, INC. (US) 2017-10-31 US disclosed
US-20170066753-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF DENALI THERAPEUTICS, INC. 2017-03-09 US disclosed
US-20170066753-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF DENALI THERAPEUTICS, INC. 2017-03-09 US disclosed
US-20170066753-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF DENALI THERAPEUTICS, INC. 2017-03-09 US disclosed
WO-2016201168-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF FORUM PHARMCEUTICALS INC. (US) 2016-12-15 WO disclosed
WO-2016171743-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS THE JOHNS HOPKINS UNIVERSITY (US) 2016-10-27 WO disclosed
WO-2015087094-A1 NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SEMMELWEIS EGYETEM (HU) 2015-06-18 WO disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 US disclosed
WO-2009098448-A1 COMPOUNDS ASTRAZENECA AB (SE) 2009-08-13 WO disclosed
WO-2004018462-A1 QUINAZOLINONE DERIVATIVES CELLTECH R & D LIMITED (GB) 2004-03-04 WO disclosed
EP-0279263-B1 INDOLE, BENZOFURAN, BENZOTHIOPHENE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1993-08-04 EP disclosed
US-4873259-A Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1989-10-10 US disclosed
EP-0279263-A2 Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1988-08-24 EP disclosed
EP-0230053-A2 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids AMERICAN CYANAMID COMPANY (US) 1987-07-29 EP disclosed
US-4006234-A Substituted 2-benzofuranyl propenones as anti-tubercular agents AMERICAN CYANAMID COMPANY (US) 1977-02-01 US disclosed
US-3931157-A ANTITUBERCULAR AMERICAN CYANAMID COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066753-A1 OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF PSEN2, SMN1; SMN2, OTC KDM4E 3178/4885HSD17B10 602/4885ALDH1A1 1137/4885
US-20200270232-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 KDM4E 4626/4885HSD17B10 2635/4885ALDH1A1 4073/4885
US-20090298807-A1 Compounds PKD1, SLC10A1, ABCB11 KDM4E 3670/4885HSD17B10 362/4885ALDH1A1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.